GuineaTuberculosis profile
Population  2014 12 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.6 (2.6–4.8) 29 (21–39)
Mortality (HIV+TB only) 1.5 (1.2–1.8) 12 (10–15)
Prevalence  (includes HIV+TB) 31 (17–50) 253 (137–403)
Incidence  (includes HIV+TB) 22 (19–24) 177 (156–199)
Incidence (HIV+TB only) 4.7 (3.9–5.5) 38 (32–45)
         
Case detection, all forms (%) 54 (48–61)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
150 (26–270) 81 (21–140)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 6 449   473
Pulmonary, clinically diagnosed 2 334   0
Extrapulmonary 2 478   0
       
Total new and relapse 11 734    
Previously treated, excluding relapses 0    
Total cases notified 11 734    
Among 11 261 new cases:
410 (4%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 114 (2%) 181 (38%) 362
Laboratory-confirmed RR-/MDR-TB cases     105
Patients started on MDR-TB treatment ***     124
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 383 (63)
HIV-positive TB patients 1 815 (25)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 768 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 1 353 (75)
HIV-positive people screened for TB 532  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (79) 11 313
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013 (75) 1 959
RR-/MDR-TB cases started on second-line treatment in 2012 (80) 15
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 6.5
% Funded domestically 19%
% Funded internationally 66%
% Unfunded 16%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-30 Data: www.who.int/tb/data